Low circulating CD34+ cell count is associated with poor prognosis in chronic hemodialysis patients
Author(s) -
Shoichi Maruyama,
Akihiko Taguchi,
Shigejiro Iwashima,
Takenori Ozaki,
Kaoru Yasuda,
Akie KikuchiTaura,
Toshihiro Soma,
Hideki Ishii,
Toyoaki Murohara,
Hiroshi Takahashi,
Hirotake Kasuga,
Yoshitaka Kumada,
Takanobu Toriyama,
Yasuhiko Ito,
Hirohisa Kawahara,
Yukio Yuzawa,
Seiichi Matsuo
Publication year - 2008
Publication title -
kidney international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.499
H-Index - 276
eISSN - 1523-1755
pISSN - 0085-2538
DOI - 10.1038/ki.2008.495
Subject(s) - cd34 , medicine , population , progenitor cell , biomarker , hemodialysis , flow cytometry , immunology , gastroenterology , stem cell , biology , genetics , biochemistry , environmental health
Circulating CD34-positive (CD34(+)) cells, a population that includes endothelial progenitor cells, are believed to contribute to vascular homeostasis. Here we determine the prognostic value of CD34(+) cell measurements in 216 chronic hemodialysis patients. A total of 43 cardiovascular events and 13 deaths occurred over an average 23 months follow-up in this cohort. A cutoff number for circulating CD34(+) cells was determined by receiver operating characteristic curve analysis to maximize the power of the CD34(+) cell count in predicting future cardiovascular events. Based on this, 93 patients were categorized as having low and 123 patients as having high numbers of CD34(+) cells, determined by flow cytometry at the time of enrollment. Both cumulative cardiovascular event-free survival and all-cause survival were significantly less in the group of patients with low numbers of CD34(+) cells. By multivariate analyses, a low level of circulating CD34(+) cells was an independent and significant predictor for both cardiovascular events and all-cause mortality. Our study shows that a reduced number of circulating CD34(+) cells is significantly associated with vascular risks and all-cause mortality in patients on chronic hemodialysis. These cells may be a useful biomarker.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom